Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Eisai/Biogen’s Alzheimer’s Candidate BAN2401 Disappoints in PII
Eisai and Biogen said on December 21 that an independent data monitoring board concluded that one of their Alzheimer’s candidates, BAN2401, failed to meet the primary endpoint at 12 months in a PII trial, but that the study will still…
To read the full story
Related Article
- Eisai Going Ahead with Global PIII for BAN2401 despite Aducanumab Setback
March 25, 2019
- Eisai, Biogen Tout BAN2401’s Clinical Effect Regardless of APOE4 Mutation
October 29, 2018
- (Update) Eisai/Biogen Alzheimer’s Drug BAN2401 Slows Cognitive Decline by 30%
July 26, 2018
- Eisai/Biogen Say Alzheimer’s Candidate BAN2401 Delivered Positive Data at 18 Month Analysis
July 9, 2018
BUSINESS
- Ultragenyx Seeks Japan Approval for GSDIa Gene Therapy
July 1, 2026
- Specialist Hails Wegovy as “Game Changer” for MASH Treatment
July 1, 2026
- Alfresa Boosts Stake in ENT Cell Sheet Startup
July 1, 2026
- Eisai, UCL Renew Neuroscience Alliance to 2030
July 1, 2026
- Asahi Kasei Nabs Japan Rights to Additional Empaveli Indications
July 1, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…